Ajanta Pharma Limited (BOM:532331)
India · Delayed Price · Currency is INR 2,918.95
+29.95 (1.04%)
At close: Feb 13, 2026
Ajanta Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 9,204 | 8,162 | 5,880 | 7,127 | 6,539 |
Depreciation & Amortization | 1,359 | 1,304 | 1,267 | 1,214 | 1,114 |
Other Amortization | 82.2 | 50.1 | 41 | 39.4 | 46.9 |
Loss (Gain) From Sale of Assets | 6 | -34.9 | 61.9 | 38.7 | 22.1 |
Loss (Gain) From Sale of Investments | -113.1 | -20.1 | 14.8 | -52.3 | 51.9 |
Stock-Based Compensation | 38.8 | 54.9 | 2.2 | 3 | 0.2 |
Other Operating Activities | -793.7 | -667.1 | -14.1 | -748.2 | 76.8 |
Change in Accounts Receivable | 804.8 | -1,789 | -105.5 | -2,697 | 311.3 |
Change in Inventory | -745.1 | -123 | -223.7 | -256.6 | -2,715 |
Change in Accounts Payable | -84.5 | 408.5 | 969.1 | -480.2 | 111.5 |
Change in Other Net Operating Assets | 1,814 | 505.5 | 28.6 | 1,430 | 204.2 |
Operating Cash Flow | 11,572 | 7,851 | 7,921 | 5,617 | 5,763 |
Operating Cash Flow Growth | 47.41% | -0.89% | 41.02% | -2.53% | 26.17% |
Capital Expenditures | -3,179 | -1,524 | -1,745 | -1,488 | -1,716 |
Sale of Property, Plant & Equipment | 11.4 | 133.8 | 7.3 | 183.8 | 17.1 |
Investment in Securities | -1,040 | 1,776 | -3,907 | 287.8 | -1,255 |
Other Investing Activities | 442.4 | 267.9 | 48.7 | 275.8 | 129.7 |
Investing Cash Flow | -3,765 | 653.9 | -5,596 | -741 | -2,824 |
Long-Term Debt Issued | 11 | 0.6 | - | 2.3 | - |
Total Debt Issued | 11 | 0.6 | - | 2.3 | - |
Long-Term Debt Repaid | -114.6 | -125.5 | -112.3 | -137.5 | -626 |
Total Debt Repaid | -114.6 | -125.5 | -112.3 | -137.5 | -626 |
Net Debt Issued (Repaid) | -103.6 | -124.9 | -112.3 | -135.2 | -626 |
Issuance of Common Stock | 0.1 | - | - | - | - |
Repurchase of Common Stock | -3,513 | -3,883 | - | -2,856 | -1,354 |
Common Dividends Paid | -3,494 | -6,422 | -896.9 | -822.1 | -829 |
Other Financing Activities | -223.5 | -81.3 | -72.8 | -783.9 | -373.8 |
Financing Cash Flow | -7,334 | -10,511 | -1,082 | -4,597 | -3,183 |
Net Cash Flow | 473 | -2,006 | 1,243 | 279 | -243.6 |
Free Cash Flow | 8,393 | 6,327 | 6,176 | 4,129 | 4,047 |
Free Cash Flow Growth | 32.66% | 2.44% | 49.59% | 2.02% | 86.20% |
Free Cash Flow Margin | 18.06% | 15.03% | 16.50% | 12.36% | 14.01% |
Free Cash Flow Per Share | 67.05 | 50.21 | 48.20 | 31.84 | 30.98 |
Cash Interest Paid | 207.4 | 72.1 | 58.4 | 102 | 49.6 |
Cash Income Tax Paid | 3,230 | 3,121 | 1,513 | 2,391 | 2,304 |
Levered Free Cash Flow | 6,621 | 1,165 | 8,146 | 1,893 | 3,096 |
Unlevered Free Cash Flow | 6,750 | 1,210 | 8,183 | 1,956 | 3,148 |
Change in Working Capital | 1,789 | -997.8 | 668.5 | -2,004 | -2,088 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.